Navigation Links
International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results
Date:11/11/2008

Nine-Months Revenue Increases 23% Compared to 2007; Gross Profit Percentage

Increases from 45% to 50% of Revenue

IDAHO FALLS, Idaho, Nov. 11 /PRNewswire-FirstCall/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the third quarter and nine-months ending September 30, 2008.

Revenue for the three and nine-month period ended September 30, 2008, was $1,245,164 and $4,429,144 respectively as compared to $1,486,112 and $3,592,049 for the same periods in 2007, a decrease of $240,948, or 16%, for the three-month period and an increase of $837,095, or 23%, for the nine-month period. The increase in total revenue for the nine-month period was attributable to strong performance in cobalt and radiochemical product business segments. The decline in revenue for the three-month period was attributable to normal variations in the sale of bulk cobalt for the period comparisons. Since the timing of large bulk cobalt product sales during the course of the calendar year has a significant impact upon period comparisons, the Company believes excluding sales of bulk cobalt product from the period comparisons of revenue provides useful information to investors.

Excluding bulk cobalt sales, revenue for the three-month period ended September 30, 2008 was $1,245,164 as compared to $1,038,835 for the same period in 2007, which represents an increase of 20%. Excluding bulk cobalt product sales, revenue for the nine-month period ended September 30, 2008 was $3,940,888 as compared to $3,144,773 for the same period in 2007, which represents an increase of 25%. Please refer to the following tables for a further analysis of this measure:

Three-Month Financial Measure Reconciliation

Period Ended Period Ended

Sept. 30, 2008 Sept. 30, 2007

Total Revenue $1,245,164
'/>"/>

SOURCE International Isotopes Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. U of T professor first Canadian woman to win prestigious international science prize
2. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
3. Health Care Workers Get Help Fighting Unprecedented Attacks from Service Employee International Union Leadership
4. Ceasefire Broken in Democratic Republic of Congo; International Medical Corps Warns of Looming Humanitarian Catastrophe and Wider Regional Impact
5. Easter Seals Elects Kent Schien, Chief Executive Officer of St. Louis-based Innoventor, to the Organizations International Board of Directors
6. Schiff(R) Nutrition International Declares November Give Thanks for Grandparents Month
7. DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results
8. Joslin researcher named first winner of the Manpei Suzuki International Prize for Diabetes Research
9. Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board
10. EarthSearch Communications International Joins Motorola's Enterprise Mobility Business PartnerSelect Program
11. International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...2 Holly Potter, vice president, Pu...agement for Kaiser Permanente, received the "PR Te...held at the National Press Club. ,, PR News,...nnovators and professionals who day in and day out...ce. The winners of this year,s program set the ben...
(Date:12/2/2009)...., Dec. 2 From more than 1,100 pho...ning, joy and peace, the LIFE Foundation has selec...d using the popular photo-sharing Web site flickr....ontage on the LIFE Foundation,s Web site at www.l...submitted one photo and a caption to Flickr.com du...
(Date:12/2/2009)...c. 2 US Farms, Inc. (Pin..., Nursery and Wellness products, is pleased to ann...ts at the Cook,sware A,faire in Oakland, Calif., a...or additional information, contact US Farms, Inc. ...it http://cookswareafaire.com ,, Victor Brand...
(Date:12/2/2009)...., Dec. 2 Watson Pharmac... the Federal Trade Commission (FTC) has accepted a...g to Watson,s pending acquisition of privately hel... the Hart Scott Rodino waiting period, thereby per... parties have now obtained all regulatory approval...
(Date:12/2/2009)...Red Cross also part of the Hewlett-Packard Company...2 The Hewlett-Packard C...lion this year to help fund American Red Cross dis...com/cgi-bin/prnh/20090108/RedCrossLOGO ) ,, Th...p Philippine communities affected by typhoons in S...
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 3Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Watson Receives FTC Clearance for Arrow Acquisition 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3
...rs , , President, Campaign for Tobacco-Free Kids ...delivered a tremendous victory for children,s heal...cluding a 61-cent increase in the cigarette tax, t...illions of children both by reducing tobacco use -...
...cuts complications that could cost them a limb , ...ombination of bone cement and antibiotics may help...mpound (open) fractures suffered by U.S. soldiers ...bacter baumannii is common in the Middle East and...
...hursday, February 5th, GlaxoSmithKline plc (NYSE: ...ts for the year ended December 31, 2008. The anno...ock Exchange at approximately 7:00 AM Eastern St...ng for analysts and investors. The meeting is avai...
.../PRNewswire-Asia/ -- Chindex International, Inc.,(...rovider of western healthcare,products and service...ed that,it plans to release fiscal third quarter 2...al results. , To participate in the conference...
...ALO ALTO, Calif., Jan. 29 ,Diagnosoft, Inc., an in...software that assists in diagnosis, staging and th...s announced the closing of $4 million in Series B...f,Diagnosoft(R) HARP(TM), Diagnosoft(R) PLUS, and ...
...andards offer framework for employers , , WASHING...t accreditation body, and the National Business Co...nsive PBM Purchasers Guide for employers and busin...Managing PBM Services is available as a free downl...
Other Medicine News:Health News:U.S. Senate Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes 2Health News:Old Tech Helps Soldiers With New Wound Infection 2Health News:Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Results 2Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 2Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 3Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 4Health News:PBM Purchaser Guide from URAC and NBCH Will Help Employers and Business Coalitions Evaluate, Manage Pharmacy Benefit Services 2Health News:PBM Purchaser Guide from URAC and NBCH Will Help Employers and Business Coalitions Evaluate, Manage Pharmacy Benefit Services 3
(Date:12/2/2009)...ecember 2 Cardio Vascula...per of advanced,cardiovascular surgery technology,...tors approved a one-for-three forward stock split,...o Vascular Medical Device shareholders. , ...ated date the stock,split will be payable and the ...
(Date:12/2/2009)...2 Roche (SIX: RO, ROG; O...s Food & Drug Administration (FDA) approved an...acid test, to screen source plasma in pools compri...lled the cobas® TaqScreen MPX Test for use on...tro test for the simultaneous, direct detection of...
(Date:12/2/2009)...., Dec. 2 Novartis announced today...tion on Tasigna® (nilotinib) 200 mg capsules ... the strength of the company,s hematology portfoli...w data, at the 51st American Society of Hematology...e company,s current therapies and investigational ...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 1American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 2National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 1National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 2Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 1Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 2
...ene Activity and Metabolic,Enzymes Show How Cells ...zyme A, a Key Player in the Daily Biochemical Rout...2007 /PRNewswire/ -- Investigators at,St. Jude Chi...the,dynamic genetic and biochemical changes that m...le called Coenzyme A (CoA), a key,player in metabo...
...07 /PRNewswire/ -- DiObex,Inc., a privately- held...ent of therapeutics to treat metabolic diseases, t...902, a novel Cortisol,Synthesis Inhibitor. , In a ...bo-controlled trial, patients with type 2 diabetes..., pharmacokinetics and,activity of three dose leve...
Other Medicine Technology:Study Shows Metabolic Strategy of Stressed Cell 2Study Shows Metabolic Strategy of Stressed Cell 3Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 2Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 3
Woodson Elevator
Henner Elevator
Tenzel Double-Ended Periosteal Elevator
DesMarres Lid Retractor
Medicine Products: